Basic information Safety Related Supplier
ChemicalBook >  Product Catalog >  API >  Inhibitors >  Niraparib

Niraparib

Basic information Safety Related Supplier
Niraparib Basic information
Niraparib Chemical Properties
  • Boiling point:463.6±45.0 °C(Predicted)
  • Density 1.34
  • pka15.36±0.30(Predicted)
Niraparib Usage And Synthesis
  • Description(S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide is also known as MK-4827(Niraparib) tosylate is a selective inhibitor of PARP1/PARP2 (The poly(ADP-ribose) polymerase) with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It has been recently approved by FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy. In vitro studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, apoptosis and cell death.
  • PharmacologyThe synthesis and initial pharmacology of niraparib have been published. Niraparib has affinity for PARP 1 and 2 inhibition (IC50 = 3.8 and 2.1 nM, respectively) and inhibits the proliferation of cancer cells with mutant BRCA1 and BRCA2 with IC50 values in the 10–100 nM range in vitro. Niraparib demonstrated efficacy as a single agent in a xenograft model of BRCA1-deficient cancer. Niraparib has also been reported to act as a preclinical radiosensitiser and has entered into clinical oncology trials.
  • Referenceshttps://newdrugapprovals.org/2016/12/22/niraparib-mk-4827/
    https://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm548487.htm
    https://www.drugbank.ca/drugs/DB11793
    Sandhu, Shahneen K, et al. "The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA, mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial." Lancet Oncology14.9 (2013):882.
    Jones, P, et al. "Niraparib: A Poly (ADP-ribose) Polymerase (PARP) Inhibitor for the Treatment of Tumors with Defective Homologous Recombination. " Journal of Medicinal Chemistry 58.8(2015):3302-14.
Niraparib(1038915-60-4)Related Product Information
NiraparibSupplierMore
  • Company Name:Liverpool ChiroChem Gold
  • Tel:13852605272 0523-86810091
  • Email:sales@chirochem.cn
  •  
  • Company Name:Taizhou Ruishinuo Pharmaceutical Technology Co., Ltd. Gold
  • Tel:19952992164
  • Email:725236090@qq.com;rainsonwpharma@163.com;
  •  
  • Company Name:Jiangsu yize medical technology co. LTD Gold
  • Tel:18351296781
  • Email:3394205705@qq.com
  •  
  • Company Name:Hubei Dibai Chemical Co., Ltd. Gold
  • Tel:15872383390 027-87058617-
  • Email:hbdibo@163.com;1024561249@qq.com;
  •  
  • Company Name:Guangzhou Zhiya Chemdrugs Co.,Ltd Gold
  • Tel:
  • Email:sculk28@163.com
  •